340B Drug Pricing Program
The House Energy & Commerce Subcommittee on Oversight and Investigations today held a hearing to review the Health Resources and Services Administration’s oversight of the 340B Drug Pricing Program and how the program impacts patients, providers, manufacturers and other stakeholders.
The AHA July 13 criticized proposed deep cuts to how much the Centers for Medicare & Medicaid Services reimburses hospitals for drugs acquired under the 340B Drug Pricing Program and proposes changes to site-neutral payment policies under Section 603 of the 2015 Bipartisan Budget Act.
On July 13, the CMS released two calendar year 2018 proposed rules: the outpatient prospective payment system/ambulatory surgical center proposed rule and the Medicare physician fee schedule proposed rule.
The Centers for Medicare & Medicaid Services today proposed to update hospital outpatient prospective payment system rates by 1.75% in calendar year 2018 compared to CY 2017. The rule also would drastically cut Medicare payment for drugs that are acquired under the 340B Drug Pricing…
Press Release
Statement on Proposed CY 2018 OPPS Rule
Tom Nickels
Executive Vice President
American Hospital Association
July 13, 2017
Today, CMS issued several poorly designed policies that will do real damage to patients’ access to care.
Reps. Peter Welch (D-VT) and Gregg Harper (R-MS) yesterday introduced the Closing Loopholes for Orphan Drugs Act (H.R. 2889, legislation that would limit the “orphan drug” exclusion for 340B Drug Pricing Program rural and cancer hospitals.
Press Release
Statement on Senate HELP Committee Hearing on Drug Pricing
Tom Nickels
Executive Vice President
American Hospital Association
The Health Resources and Services Administration today delayed to Oct. 1 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers. The final rule was subject to multiple delays since January.
The Health Resources and Services Administration today delayed to May 22 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers, and invited comments on whether a delay to Oct. 1 would be more appropriate.